Public Health Landscape
HIV and cervical remain serious public health challenges. In early 2018, PEPFAR reassessed its cervical cancer prevention strategy in collaboration with Pink Ribbon Red Ribbon, evaluating progress made over the past five years and assessing the gaps. HIV-positive women were identified as the highest risk, so PEPFAR developed an age-band appropriate, comprehensive strategy to reduce cervical cancer risk by 95% in HIV-positive women by every-other-year cervical cancer screening for HIV-positive women over the age of 30, and human papilloma virus vaccination in younger girls and women living with HIV.
In 2016, Ethiopia had 30,000 new HIV infections and 710,000 people living with HIV, among whom 59% were accessing antiretroviral therapy and 51% had suppressed viral loads, according to UNAIDS.org.* Quick facts related to the public health landscape in Ethiopia are highlighted below, as retrieved from the “CDC Division of Global HIV & TB Country Profile” (July 2018) and the “World Health Organization Cancer Country Profile (2014).”
- – Estimated HIV prevalence (ages 15-49): 0.9% (2017)
- – Estimated AIDS deaths (ages 15 and above): 12,000 (2017)
- – Estimated orphans due to AIDS: 330,000 (2017)
- – Reported number receiving antiretroviral therapy (ages 15 and above): 415,578 (2017)
- – Female cancer mortality profile: 17.5% (2014)
- – Female cancer incidence: 7,095 (2014)
Cardno’s Contribution to PEPFAR Goals
In an effort to combat the epidemic, Cardno’s P4 Project (and many others) partnered with the Pink Ribbon Red Ribbon Ethiopia Partnership to increase demand and access to quality cervical cancer screening and prevention services to women, especially those living with HIV/AIDS in target regions. The partnership also supports procurement of commodities and supplies and capacity building of health workers.
In addition to the Pink Ribbon Red Ribbon Ethiopia Partnership, in 2007, Office of the U.S. Global AIDS Coordinator (OGAC) and Becton, Dickinson and Company (BD) combined their respective strengths, experience, methodologies, and resources to pursue a public-private partnership. The BD-PEPFAR Laboratory Strengthening Partnership was coordinated by the International Laboratory Branch of CDC on behalf of OGAC, and supported specific laboratory strengthening projects relevant to TB and HIV/AIDS treatment and care in PEPFAR countries. The partnership was implemented in Ethiopia, Uganda, Mozambique, and South Africa. The partnership concluded its fifth year of implementation in 2012 and OGAC commissioned Cardno to conduct a third-party assessment of the partnership. The assessment documented the value added of the partnership in terms of BD and PEPFAR shared goals and objectives, resources leveraged, and the results achieved through the partnership. The assessment documented potential opportunities for scale-up and replication of such partnerships. Finally, the assessment distilled the lessons learned from the partnership and provided recommendations on how these lessons can be transferred to the partnership’s second phase, Labs for Life, launched at the International AIDS Conference 2012.
* Data retrieved in September 2018 from unaids.org.
**Data retrieved in September 2018 from www.cdc.gov/globalhivtb.
***Data retrieved in September 2018 from www.who.int/cancer/country-profiles.